UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Feb

    12

    Providing U.S. Policy Actions on Rare Disease

    Read More

    Feb

    03

    Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented

    Read More

    Jan

    31

    Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape

    Read More

    Jan

    16

    UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

    Read More

    Dec

    18

    Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions

    Read More

    Dec

    06

    UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

    Read More

    Nov

    26

    UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

    Read More

    Nov

    20

    Closing gaps in HS care through community engagement and scientific innovation

    Read More

    Nov

    20

    UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

    Read More

    Nov

    14

    New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

    Read More